Clinical trial
A Phase Ⅳ, Randomized, Controlled, Open-label, Immunogenicity Study of Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
NCT06331702 is registered in ClinicalTrials.gov with Liaoning Chengda Biotechnology CO., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅳ, Randomized, Controlled, Open-label, Immunogenicity Study of Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
- Lead sponsor
- Liaoning Chengda Biotechnology CO., LTD
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 2, 2024
- Completion date
- February 11, 2025
- Enrollment
- 408 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.